65,437 trials
Ebola Viruses
Primary: Percentage of Participants With 1 or More Unsolicited AE : Vaccination 1 — 60.0; 70.0; 50.0; 44.4 Percentage of participants
Breast Cancer
Primary: Disease-free Survival (DFS) Event — 98; 71 Participants
Ivermectin
Primary: The Number of Cytokines Showing Statistically Significant Changes From Pre-treatment Levels Will be Recorded. — 0; 0; 0; 0 Cytokines changed from t=0
Sexual Dysfunctions, Psychological · Hypoactive Sexual Desire Disorder · Erectile Dysfunctions
Primary: Number of Participants With a Score of ≤2 (Much/Very Much Improved) on the Clinical Global Impression Scale Adapted for Sexual Function (CGI-SF) at Week 6 Between…
Paroxysmal Nocturnal Hemoglobinuria
Primary: Change From Baseline in Lactate Dehydrogenase — -15.9 Units/Liter — p=<0.001
Hypoparathyroidism
Primary: Baseline-adjusted Cmax of PTH(1-84) — 295.662; 330.820; 175.468; 99.708 Picogram per milliliter (pg/mL)
Phenylketonuria (PKU)
Primary: Change From Baseline in the Blood Plasma Phenylalanine (Phe) Concentration at Part 2 — 596.8; 563.9; 410.9; 508.2 µmol/L — p=<0.0001
Adrenoleukodystrophy · Metachromatic Leukodystrophy · Globoid Cell Leukodystrophy
Primary: Number of Patients With Donor Cell Engraftment — 26 Participants
Chronic Lymphocytic Leukemia · Prolymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma
Primary: Overall Survival — 34 Participants
Retinitis Pigmentosa
Primary: Number of Participants With Serious and Non-Serious Adverse Events — 11; 13; 3 Participants
Smoking
Primary: Change From Baseline in True Positives on the 3-Back Level of the Letter-N-Back Neurocognitive Task at Day 28 (i.e., Week 4) — .59; 3.4 True positive responses
HIV Prevention
Primary: Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms Within 3 Days of Any Product Administration — 3; 3; 3; 2 Participants
Heart Failure
Primary: Overall Survival on Device — 52.9 Percent Probability of Survival
Mucopolysaccharidosis I · Hurler Syndrome
Primary: Number of Patients Alive at One Year Post Transplant — 18 Participants
HIV · Salivary Gland Disease · Benign Lymphoepithelial Lesion
Primary: BK Viral Status in Saliva at Week 4 — 3; 6; 5; 1 Participants